Acute Leukemias: Mastering the Latest Developments in the Absence of Targetable Mutations

Gain insights into the latest advances in the use of new approaches for treating patients with ALL and AML, including biomarkers, new targeted agents, safety considerations, and clinical trials, through expert-guided discussion and case-based examples.
Stéphane de Botton, MD
David Marks, MD, PhD

Downloadable Slidesets

Download this short slideset of key takeaways from a live CCO Webinar focused on the latest developments in acute leukemias.

Stéphane de Botton, MD David Marks, MD, PhD Released: July 14, 2020

Download these slides to review expert insights on optimizing treatment for patients with ALL.

David Marks, MD, PhD Released: July 10, 2020

Download these slides to review expert insights on the latest developments in the treatment of patients with AML

Stéphane de Botton, MD Released: July 10, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?